Evidence map›Paper›PMID 22936662›Full record

ArticleBlood2012

Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

Friederike Langhauser, Eva Göb, Peter Kraft, Christian Geis, Joachim Schmitt, Marc Brede, Kerstin Göbel, Xavier Helluy, Mirko Pham, Martin Bendszus and 6 more

Open access · greenAbstract read
In one paragraph

Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The kallikrein-kinin system modulates CD4Journal of neuroinflammation · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. The temporal dynamic of bradykinin type 2 receptor effects reveals its neuroprotective role in the chronic phase of cerebral and retinal ischemic injury.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Human serum proteomics reveals a molecular signature after one night of sleep deprivation.Sleep advances : a journal of the Sleep Research Society · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Friederike LanghauserDepartment of Neurology, University of Würzburg, Würzburg, Germany.
Eva Göb
Peter Kraft
Christian Geis
Joachim Schmitt
Marc Brede
Kerstin Göbel
Xavier Helluy
Mirko Pham
Martin Bendszus
Peter Jakob
Guido Stoll
Sven G Meuth
Bernhard Nieswandt
Keith R McCrae
Christoph Kleinschnitz
University of Würzburg · DEHeidelberg University · DEUniversity of Münster · DECleveland Clinic Lerner College of Medicine · USInstitute of Pharmacology · CZUniversitätsklinikum Würzburg · DE

Funding

Regulation of Angiogenesis by KininogenR01HL089796 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCRAE, KEITH R. · 2009 to 2013
$2.0M
NHLBI NIH HHS R01 HL089796
6 · The paper itself

Abstract

Thrombosis and inflammation are hallmarks of ischemic stroke still unamenable to therapeutic interventions. High-molecular-weight kininogen (KNG) is a central constituent of the contact-kinin system which represents an interface between thrombotic and inflammatory circuits and is critically involved in stroke development. Kng(-/-) mice are protected from thrombosis after artificial vessel wall injury and lack the proinflammatory mediator bradykinin. We investigated the consequences of KNG deficiency in models of ischemic stroke. Kng(-/-) mice of either sex subjected to transient middle cerebral artery occlusion developed dramatically smaller brain infarctions and less severe neurologic deficits without an increase in infarct-associated hemorrhage. This protective effect was preserved at later stages of infarction as well as in elderly mice. Targeting KNG reduced thrombus formation in ischemic vessels and improved cerebral blood flow, and reconstitution of KNG-deficient mice with human KNG or bradykinin restored clot deposition and infarct susceptibility. Moreover, mice deficient in KNG showed less severe blood-brain barrier damage and edema formation, and the local inflammatory response was reduced compared with controls. Because KNG appears to be instrumental in pathologic thrombus formation and inflammation but dispensable for hemostasis, KNG inhibition may offer a selective and safe strategy for combating stroke and other thromboembolic diseases.

Indexed as

AnimalsBlood-Brain BarrierBrainBrain EdemaBrain IschemiaDisease Models, AnimalFemaleInflammationIntracranial HemorrhagesKininogensMagnetic Resonance ImagingMaleMiceMice, KnockoutRegional Blood FlowStrokeKininogens

Identifiers

PMID22936662
PMCPMC3543983
OpenAlexW1969886260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.